Isoprinosine in the treatment of chronic active hepatitis type B.
21 patients with chronic active hepatitis B (CAH-B) were treated for 1-2 years with isoprinosine, while another 18 patients served as control group. All patients were initially DNA polymerase (DNAp) and HBeAg positive. Nine (43%) treated patients became persistently negative for DNAp, seroconverted to anti-HBe and showed histological remission on follow-up biopsy. Among simultaneously followed controls 5 (28%) lost DNAp and 4 (22%) also lost their HBeAg. However, only 2 (11%) seroconverted to anti-HBe. Histological improvement was seen in 5 (28%) controls. Thus, it seems that isoprinosine may exert a beneficial effect on the course and outcome of CAH-B.
Cianciara
J
J
Department of Hepatology, Institute of Infectious and Parasitic Diseases, Warsaw, Poland.
Laskus
T
T
Gabinska
E
E
Loch
T
T
D000328:Adult; D004259:DNA-Directed DNA Polymerase / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006513:Hepatitis B e Antigens / Q000032:analysis; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male
D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D004259:DNA-Directed DNA Polymerase; D007542:Inosine Pranobex